No Evidence of a Drug-Drug Interaction Between Letermovir (MK-8228) and Mycophenolate Mofetil [PDF]
, 2015 Introduction: Letermovir (MK-8228) is a potent, oncedaily inhibitor of the cytomegalovirus (CMV) terminase complex that is being developed for the prophylaxis of CMV infection in transplant patients. This study evaluated the pharmacokinetic interactions,
Badshah, C. +9 more
core +2 more sources
Immunity, Inflammation and Disease, 2021 Letermovir prophylaxis in allogeneic hematopoietic cell transplant recipients significantly reduces the incidence of clinically significant cytomegalovirus infection. However, breakthrough infections still occur despite adequate prophylaxis.
Léna Royston +5 more
doaj +1 more source
Pharmaceutical Fronts, 2021 A series of mono- or bis-quaternary ammonium salts derived from cinchonidine or quinine was synthesized and screened as potent phase-transfer catalysts for the reaction of aza-Michael cyclization, the key step in the synthesis of letermovir.
Liang Chen +7 more
doaj +1 more source
Estimation of the worldwide seroprevalence of cytomegalovirus : a systematic review and meta-analysis [PDF]
, 2019 Cytomegalovirus (CMV) infection does not usually produce symptoms when it causes primary infection, reinfection, or reactivation because these three types of infection are all controlled by the normal immune system.
Anderholm +31 more
core +2 more sources
Changes in subcellular localization reveal interactions between human cytomegalovirus terminase subunits [PDF]
, 2012 BACKGROUND: During herpesvirus replication, terminase packages viral DNA into capsids. The subunits of herpes simplex virus terminase, UL15, UL28, and UL33, assemble in the cytoplasm prior to nuclear import of the complex.
McVoy, Michael A. +3 more
core +2 more sources
Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant patients: a single-arm open-label phase I clinical trial [PDF]
, 2018 BACKGROUND: Opportunistic infections including cytomegalovirus (CMV) are a major cause of morbidity and mortality in solid organ transplant (SOT) recipients.
Beagley, Leone +13 more
core +1 more source
Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong [PDF]
, 2020 Background: The cost-effectiveness of letermovir as cytomegalovirus (CMV) prophylaxis in adult seropositive patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), compared with the conventional strategy of preemptive treatment ...
Alsumalli, A +7 more
core +1 more source
Isolation and characterization of the herpes simplex virus 1 terminase complex [PDF]
, 2013 During herpes simplex virus 1 (HSV-1) infection, empty procapsids are assembled and subsequently filled with the viral genome by means of a protein complex called the terminase, which is comprised of the HSV-1 UL15, UL28, and UL33 proteins.
Heming, Jason D +3 more
core +2 more sources
Cytomegalovirus drug resistance mutations in transplant recipients with suspected resistance [PDF]
, 2023 Resistant CMV infections are challenging complications after SOT and HSCT. Prompt recognition of ARMs is imperative for appropriate therapy. 108 plasma samples from 96 CMV + transplant recipients with suspected resistance were analysed in CNM in a ...
Gonzalez-Jimenez, Irene +2 more
core +1 more source
Clinical Infection in Practice, 2020 Reported is a case of cytomegalovirus ventriculitis on a background of HIV infection. Sequencing demonstrated viral mutations conferring resistance to available therapies.
Andrew Bosworth +7 more
doaj +1 more source